Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 2/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101238 | 1.00 | MAPT (0.56) | MAPTKDM4EGAALMNAHTT | |
| SCHEMBL18101265 | 1.00 | MAPT (0.56) | MAPTKDM4EGAALMNAHTT | |
| SCHEMBL18101286 | 1.00 | MAPT (0.56) | MAPTKDM4EGAALMNAHTT | |
| SCHEMBL110634 | 0.94 | CD274 (0.57) | MAPTKDM4EGAALMNAHTT | |
| Hydrochloric Acid SCHEMBL3761404 | 0.92 | CD274 (0.55) | MAPTKDM4EGAALMNAHTT | |
| SCHEMBL111534 | 0.86 | TAAR1 (0.52) | MAPTGAALMNACD274TAAR1 | |
| SCHEMBL29463278 | 0.82 | TAAR1 (0.71) | MAPTGAATAAR1CYP2D6SLC6A4 | |
| SCHEMBL57649 | 0.82 | TAAR1 (0.71) | MAPTGAATAAR1CYP2D6SLC6A4 | |
| SCHEMBL12764442 | 0.81 | LMNA (0.53) | MAPTKDM4EGAALMNAHTT | |
| SCHEMBL18101275 | 0.81 | MAPT (0.53) | MAPTKDM4EGAALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | TECAN SP, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | CYP2C8, CES2, UGT1A8 | MAPT 2114/4885KDM4E 152/4885GAA 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.